Investigation Report on China Ezetimibe Market, 2010-2019
Description
With the sustained economic development and the improvements in diet, Chinese people’s blood fat level rises too. Many local epidemiological studies on blood fat have proved that a conservative estimate of the incidence of hyperlipemia is 7%-8% while the actual incidence might be above 10%. Over 100 million people in China have to receive cholesterol-lowering therapy, more so with the coming ageing society. As people increasingly pay attention to health, cholesterol-lowering drugs will become more and more promising. The annual market size of statin drug is estimated to surpass USD 20 billion around the world, growing at an annual rate of 20% .
Ezetimibe, the first cholesterol absorption selective inhibitor in the world, was jointly developed by Merck and Schering-Plough and approved by FDA in 2002 as the first drug for regulating blood fat with completely innovative mechanism of action after statin. Ezetimibe can selectively inhibit cholesterol transporter in the small intestine, effectively reduce cholesterol absorption, lower plasma cholesterol level and decrease the amount of cholesterol normally available to liver cells. As an ideal partner of statin, ezetimibe can provide better control rates for LDL-C with good safety and tolerance than doubled statin dose or more potent statin.
Ezetimibe in the Chinese market is monopolized by Schering-Plough. Ezetimibe develops fast after entering China with annual sales rising from less than CNY 0.05 million in 2007 to CNY 20.67 million in 2014 and CAGR during this period reaching up to 137%.
Ezetimibe enjoys a vast demand in China and its market size is expected to grow in the next few years.
Readers can get at least the following information from this report:
With the sustained economic development and the improvements in diet, Chinese people’s blood fat level rises too. Many local epidemiological studies on blood fat have proved that a conservative estimate of the incidence of hyperlipemia is 7%-8% while the actual incidence might be above 10%. Over 100 million people in China have to receive cholesterol-lowering therapy, more so with the coming ageing society. As people increasingly pay attention to health, cholesterol-lowering drugs will become more and more promising. The annual market size of statin drug is estimated to surpass USD 20 billion around the world, growing at an annual rate of 20% .
Ezetimibe, the first cholesterol absorption selective inhibitor in the world, was jointly developed by Merck and Schering-Plough and approved by FDA in 2002 as the first drug for regulating blood fat with completely innovative mechanism of action after statin. Ezetimibe can selectively inhibit cholesterol transporter in the small intestine, effectively reduce cholesterol absorption, lower plasma cholesterol level and decrease the amount of cholesterol normally available to liver cells. As an ideal partner of statin, ezetimibe can provide better control rates for LDL-C with good safety and tolerance than doubled statin dose or more potent statin.
Ezetimibe in the Chinese market is monopolized by Schering-Plough. Ezetimibe develops fast after entering China with annual sales rising from less than CNY 0.05 million in 2007 to CNY 20.67 million in 2014 and CAGR during this period reaching up to 137%.
Ezetimibe enjoys a vast demand in China and its market size is expected to grow in the next few years.
Readers can get at least the following information from this report:
- market size of ezetimibe in China
- price of ezetimibe in Chinese market
- market outlook of ezetimibe in China The author suggests the following groups of people purchase this report:
- manufacturers of lipid-lowering drugs
- investors/ research institutions interested in Chinese medicine market
- any interest in the Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF EZETIMIBE
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF EZETIMIBE IN CHINA
2.1 Patent and Approval Status of Ezetimibe in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF EZETIMIBE IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF EZETIMIBE IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF EZETIMIBE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF EZETIMIBE IN CHINESE HOSPITALS IN 2014
7 MAJOR MANUFACTURERS OF EZETIMIBE IN CHINESE MARKET, 2010-2014
8 MARKET OUTLOOK OF EZETIMIBE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF EZETIMIBE IN CHINA
2.1 Patent and Approval Status of Ezetimibe in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF EZETIMIBE IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF EZETIMIBE IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF EZETIMIBE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF EZETIMIBE IN CHINESE HOSPITALS IN 2014
7 MAJOR MANUFACTURERS OF EZETIMIBE IN CHINESE MARKET, 2010-2014
8 MARKET OUTLOOK OF EZETIMIBE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
SELECTED CHARTS
Chart Sales Status of Ezetimibe in China
Chart Sales Value of Ezetimibe in China, 2010-2014
Chart Sales Value of Ezetimibe in Some Regions in China, 2010-2014
Chart Sales Volume of Ezetimibe in China, 2010-2014
Chart Sales Volume of Ezetimibe in Some Regions in China, 2010-2014
Chart Sales Value and Market Share of Ezetimibe Made by Schering-Plough (SI) in China, 2010-2014
Chart Sales Value and Market Share of Ezetimibe Made by Schering-Plough (Ireland) in China, 2010-2014
Chart Sales Volume and Market Share of Ezetimibe Made by Schering-Plough (SI) in China, 2010-2014
Chart Sales Volume and Market Share of Ezetimibe Made by Schering-Plough (Ireland) in China, 2010-2014
Chart Sales Value and Market Share of Ezetimibe Tablets in China, 2010-2014
Chart Sales Volume and Market Share of Ezetimibe Tablets in China, 2010-2014
Chart Price of Ezetimibe Made by Schering-Plough (Singapore) in Some Chinese Cities in 2014
Chart Sales Status of Ezetimibe in China
Chart Sales Value of Ezetimibe in China, 2010-2014
Chart Sales Value of Ezetimibe in Some Regions in China, 2010-2014
Chart Sales Volume of Ezetimibe in China, 2010-2014
Chart Sales Volume of Ezetimibe in Some Regions in China, 2010-2014
Chart Sales Value and Market Share of Ezetimibe Made by Schering-Plough (SI) in China, 2010-2014
Chart Sales Value and Market Share of Ezetimibe Made by Schering-Plough (Ireland) in China, 2010-2014
Chart Sales Volume and Market Share of Ezetimibe Made by Schering-Plough (SI) in China, 2010-2014
Chart Sales Volume and Market Share of Ezetimibe Made by Schering-Plough (Ireland) in China, 2010-2014
Chart Sales Value and Market Share of Ezetimibe Tablets in China, 2010-2014
Chart Sales Volume and Market Share of Ezetimibe Tablets in China, 2010-2014
Chart Price of Ezetimibe Made by Schering-Plough (Singapore) in Some Chinese Cities in 2014